Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Completes Cash Tender Offer for ViaCell

NEW YORK (GenomeWeb News) - PerkinElmer said today it has completed its successful tender offer to acquire ViaCell by buying more than 90 percent of the company's outstanding common stock.
 
PerkinElmer said it purchased approximately 37.9 million ViaCell shares through the tender offer, which expired Thursday night. PerkinElmer paid $7.25 a share for a total of more than $274 million.  
 
The company said it plans to buy ViaCell’s remaining shares through a short-form merger under Delaware law for the same price, at which time ViaCell will become a wholly owned PerkinElmer subsidiary.
 
When the deal is closed, PerkinElmer plans to sell ViaCell's therapeutics business
 

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.